China Pivots to Combination Vaccines to Break Foreign Monopoly
Listen to the full version
China is pivoting its vaccine development toward combination shots in a bid to modernize its heavily burdened immunization program and overcome long-standing market dominance by multinational pharmaceutical companies over high-tech biologicals.
Although the country’s national immunization program has operated for nearly 50 years — establishing a framework of “15 vaccines preventing 16 diseases” — it continues to face hurdles in vaccine innovation and rollout. At the 2026 Vaccine and Health Conference recently held in Changsha, Hunan province, industry insiders noted that multinational drugmakers have long monopolized the market for high-barrier biologicals such as pentavalent and hexavalent vaccines, setting combination shots as the imminent path forward for China’s domestic research and development.
Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations.
Save an extra $50. Introductory offer for new readers. Subscribe now.
- DIGEST HUB
Digest Hub
Back
- China pivots to combination vaccines to modernize immunization (18-20 infant doses vs. 10-11 abroad) and challenge multinational dominance in pentavalent/hexavalent shots.
- Benefits: simplified schedules, reduced risks/injections, higher compliance; Hib integration via combos recommended.
- Domestic trivalent/tetravalent available (e.g., Minhai DTaP-Hib); pentavalent imported (Sanofi); hurdles include antigen compatibility, schedule conflicts, regulatory "single first" barriers.
1. China is shifting focus to combination vaccines to modernize its immunization program and challenge multinational dominance in advanced biologicals [para. 1].
2. China's national immunization program, nearly 50 years old with "15 vaccines preventing 16 diseases," struggles with innovation; at the 2026 Vaccine and Health Conference in Changsha, experts highlighted multinational monopoly on pentavalent and hexavalent vaccines, urging domestic combination vaccine R&D [para. 2].
3. Combination vaccines mix antigens from multiple pathogens for "one shot preventing multiple diseases," offering key advantages amid policy pushes for immunization optimization [para. 3].
4. Advantages include simplified schedules reducing doses and pain (especially for infants), lower risks of cross-infection and reactions like swelling/fever, and higher compliance by avoiding missed doses [para. 4].
5. Chinese children under 2 need 18-20 doses for basic immunizations, versus 10-11 doses for 11-13 diseases in the U.S., U.K., Cambodia, and Malaysia—half the frequency [para. 5].
6. Combinations aid inclusion of non-national shots like WHO-prioritized Hib vaccine, hindered by its early dosing overlapping existing schedules [para. 6].
7. At Peking University's April 21 seminar during 2026 Immunization Week, experts cited scheduling conflicts from single vaccines and parental reluctance for multiple jabs; combining Hib would cut injections and save resources [para. 7].
8. Market gaps and regulatory hurdles persist in combination vaccine development [para. 8].
9. Domestic combos are mostly trivalent (e.g., DTaP by Minhai/Kangtai, Walvax) and tetravalent; pentavalent/hexavalent absent or imported; Zhifei's AC-Hib failed reregistration in 2019 [para. 9].
10. DTaP-Hib tetravalent, protecting against diphtheria, tetanus, pertussis, Hib, was China's first domestic combo, approved exclusively for Minhai in 2013 [para. 10].
11. Pentavalent market monopolized by Sanofi's imported Pentaxim (DTaP-IPV-Hib); Minhai's domestic version in Phase III trials [para. 11].
12. Jiankai Liu (Kangtai VP) at April 18 conference called combos the future trend; China's DTaP-pentavalent penetration <1/6th of Europe/U.S., indicating growth potential [para. 12].
13. Laws encourage combos, but R&D faces major challenges [para. 13].
14. Key barriers: antigen compatibility/immune interference reducing efficacy, plus schedule mismatches disrupting trials/registration [para. 14].
15. Example: Hep B dosing (0,1,6 months) vs. hexavalent (2,4,6 months) complicates design/approval, needing authority coordination [para. 15].
16. Both technological and policy breakthroughs needed [para. 16].
17. "Approval number barrier" required single vaccine approvals first before combos, though not explicit [para. 17].
18. 2022 regulations eased "single first" by allowing outsourcing singles, but direct combo development risks high failure in safety/efficacy evaluation without single foundations [para. 18].
- Minhai Biotechnology Co. Ltd.
- Minhai Biotechnology Co. Ltd., a subsidiary of Kangtai Biological Products Co. Ltd., produces the trivalent DTaP vaccine. It launched China's first domestic DTaP-Hib tetravalent vaccine in 2013 with exclusive approval. Its pentavalent vaccine (DTaP-IPV-Hib) is in Phase III trials.
- Kangtai Biological Products Co. Ltd.
- Kangtai Biological Products Co. Ltd. owns Minhai Biotechnology, producer of DTaP (trivalent) and DTaP-Hib (tetravalent) vaccines—China's first domestic combo shot approved in 2013. Minhai's pentavalent is in Phase III trials. VP Jiankai Liu emphasized combo vaccines' growth potential amid low market penetration.
- Walvax Biotechnology Co. Ltd.
- Walvax Biotechnology Co. Ltd. has launched the mainstream trivalent DTaP vaccine (diphtheria, tetanus, and acellular pertussis) in China.
- Zhifei Biological Products Co. Ltd.
- Zhifei Biological Products Co. Ltd. once produced the AC-Hib vaccine, but the product disappeared from the market after failing to secure reregistration when its approval expired in 2019.
- Sanofi
- Sanofi produces Pentaxim (DTaP-IPV-Hib), the only pentavalent vaccine approved in China, holding a market monopoly on these high-barrier biologicals.
- MOST POPULAR
Sign in with Google
Sign in with Facebook
Sign in with 财新